RT Journal Article
SR Electronic
T1 Dengue antibodies can cross-react with SARS-CoV-2 and <em>vice versa</em>-Antibody detection kits can give false-positive results for both viruses in regions where both COVID-19 and Dengue co-exist
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.03.20145797
DO 10.1101/2020.07.03.20145797
A1 Himadri Nath
A1 Abinash Mallick
A1 Subrata Roy
A1 Soumi Sukla
A1 Keya Basu
A1 Abhishek De
A1 Subhajit Biswas
YR 2020
UL http://medrxiv.org/content/early/2020/07/06/2020.07.03.20145797.abstract
AB Five of thirteen Dengue antibody-positive serum samples, dated 2017 (pre-dating the COVID-19 outbreak) produced false-positive results in SARS-CoV-2 IgG/IgM rapid strip tests. Our results emphasize the importance of NAT and/or virus antigen tests to complement sero-surveillance for definitive diagnosis of COVID-19/Dengue in regions where both viruses are co-endemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe project was funded by a grant from the Council of Scientific and Industrial Research, India to S.B. Grant number: MLP 130; CSIR Digital Surveillance Vertical for COVID-19 mitigation in India.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the research was granted by the respective Institutional Ethical Committee of CSIR-IICB and Calcutta National Medical College, Kolkata.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available from the corresponding author on request.